Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Ovarian Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/13/2018 |
| Start Date: | July 12, 2016 |
| End Date: | September 2019 |
| Contact: | Mark Robson, MD |
| Phone: | 646-888-4058 |
This study will evaluate patients' experiences with having gynecologic or prostate medical
oncologists and surgeons offer them genetic testing, and having genetic counselors return the
test results to patients over the telephone. This is different from the usual approach to
genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their
patients to a genetic counselor in order to have these tests done, and the genetic counselors
return the test results to the patient in person or over the telephone. The investigators
will only be evaluating this alternative way of providing genetic testing to ovarian or
prostate cancer patients.
oncologists and surgeons offer them genetic testing, and having genetic counselors return the
test results to patients over the telephone. This is different from the usual approach to
genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their
patients to a genetic counselor in order to have these tests done, and the genetic counselors
return the test results to the patient in person or over the telephone. The investigators
will only be evaluating this alternative way of providing genetic testing to ovarian or
prostate cancer patients.
Inclusion Criteria:
- MSK patient age 18 years or older.
- Diagnosed with or presumed by physician to have invasive epithelial ovarian cancer,
peritoneal cancer, or fallopian tube cancer, or prostate cancer, or pancreatic cancer.
- Deemed to be clinically appropriate for multiplex genetic testing by their MSK Gyn DMT
,GU DMT or GI DMT physician.
- Agreed to receive clinical multiplex genetic testing from their MSK Gyn DMT, GU DMT or
GI DMT physician.
- English-fluent; the surveys were designed and validated in English and are not
currently available in other languages. Translation of questionnaires into other
languages would require reestablishing the reliability and validity of these measures.
Therefore, participants must be able to communicate in English to complete the
surveys.
Exclusion Criteria:
- Patients who do not or will not receive their ongoing cancer care at MSK.
- Major psychiatric illness or cognitive impairment that in the judgment of the study
investigators or study staff would preclude study participation.
- Any patients who are unable to comply with the study procedures as determined by the
study investigators or study staff.
- For ovarian cancer patients only: patient insured by a payer that does not provide
coverage for multiplex genetic testing as delivered in this protocol (e.g., Cigna,
United Health Care, or Oxford, (because these payers require genetic counseling by a
genetics professional prior to testing).
We found this trial at
5
sites
136 Mountainview Boulevard
Basking Ridge, New Jersey 07920
Basking Ridge, New Jersey 07920
Principal Investigator: Mark Robson, MD
Phone: 646-888-4058
Click here to add this to my saved trials
Commack, New York 11725
Principal Investigator: Mark Robson, MD
Phone: 646-888-4058
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Harrison, New York 10604
Phone: 646-888-4058
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Mark Robson, MD
Phone: 646-888-4058
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials